Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3777 | Stem Cell Educator-Treated Mononuclear Cells Apheresis Wiki | 0.71 |
| drug3319 | Remdesivir Wiki | 0.13 |
| drug2916 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 2 clinical trials
Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of ivermectin in preventing progression of disease in adult patients with early stages of COVID-19
Description: Time until resolution of symptoms
Measure: Time to event Time: 21 daysDescription: Clinical condition in an ordinal scale of 7 points, on day 2. Higher scores indicate worse outcomes
Measure: Clinical condition on day 2 Time: On day 2 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 5. Higher scores indicate worse outcomes
Measure: Clinical condition on day 5 Time: On day 5 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 8. Higher scores indicate worse outcomes
Measure: Clinical condition on day 8 Time: On day 8 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 11. Higher scores indicate worse outcomes
Measure: Clinical condition on day 11 Time: On day 11 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 15. Higher scores indicate worse outcomes
Measure: Clinical condition on day 15 Time: On day 15 (± 1 day) after randomizationDescription: Clinical condition in an ordinal scale of 7 points, on day 21. Higher scores indicate worse outcomes
Measure: Clinical condition on day 21 Time: On day 21 (± 1 day) after randomizationDescription: Proportion of subjects who require hospitalization, use of supplementary oxygen for >24 hours or ICU admission
Measure: Proportion of subjects with additional care Time: 21 daysDescription: Proportion of subjects who die
Measure: Proportion of subjects who die Time: From randomization up to 21 daysDescription: Duration of supplementary oxygen, hospitalization, ICU stay
Measure: Duration of additional care Time: 21 daysDescription: Proportion of subjects who develop solicited adverse events
Measure: Adverse events Time: 21 daysDescription: Proportion of subjects who required discontinuation of the trial due to adverse events
Measure: Proportion of subjects who discontinue intervention Time: 21 daysDescription: Time until deterioration of 2 or more points in an ordinal 7 points scale.
Measure: Time to event Time: 21 daysIvermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.
Description: The primary outcome will be the viral clearance at day 6 in the intervention group compared to placebo.
Measure: Viral clearance at day 6 Time: Outcome will be determined till 6 days post interventionDescription: Secondary outcomes: viral shedding duration (time between first positive PCR to last of two consecutive negative tests)
Measure: Viral shedding duration Time: Outcome will be determined till 14 days post interventionDescription: Time between drug treatment and symptoms resolution
Measure: Symptoms clearance time Time: Outcome will be determined till 14 days post interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports